WL 8713

Drug Profile

WL 8713

Alternative Names: Anticholinergic therapeutic - Actavis; WL8713

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Actavis Inc
  • Developer Allergan
  • Class Skin disorder therapies
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hyperhidrosis

Most Recent Events

  • 09 Sep 2016 No recent reports on development identified - Phase-II for Hyperhidrosis in USA (unspecified route)
  • 01 Jun 2014 Watson Pharmaceuticals completes a phase II trial in Hyperhidrosis in USA (NCT02193139)
  • 01 Dec 2013 Phase-II clinical trials in Hyperhidrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top